Endpoints News· @endpts · X·· 5 天前AI 评分32
AI 导读
Kali Therapeutics 用 1800 万美元自建管线，而非从中国授权引进，随后将其主要资产出售给赛诺菲。为何它入选 Endpoints 11：https://endpoints.news/endpoints-11-2026-winner-kali-looked-at-china-for-pipeline-drugs-then-turned-in-house/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=
正文
Kali Therapeutics built its own pipeline on $18M instead of licensing from China, then sold its lead asset to Sanofi. Why it made the Endpoints 11: https://endpoints.news/endpoints-11-2026-winner-kali-looked-at-china-for-pipeline-drugs-then-turned-in-house/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=
来源：Endpoints News · x.com